Pharmaceutical Information |
Drug Name |
Enoxaparin |
Drug ID |
BADD_D02438 |
Description |
Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies.[L31393] Enoxaparin markedly reduces the incidence of venous thromboembolism in hospitalized patients when compared to unfractionated [heparin], without increasing the risk of serious bleeding.[A228178,A228313] |
Indications and Usage |
For the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism, and also for the prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction, when concurrently administered with aspirin. |
Marketing Status |
Not Available |
ATC Code |
B01AB01; B01AB12; C05BA03; S01XA14 |
DrugBank ID |
DB01225
|
KEGG ID |
D07510
|
MeSH ID |
D017984
|
PubChem ID |
772
|
TTD Drug ID |
Not Available
|
NDC Product Code |
Not Available |
Synonyms |
Enoxaparin | Enoxaparine | PK-10,169 | PK 10,169 | PK10,169 | PK-10169 | PK 10169 | PK10169 | EMT-967 | EMT 967 | EMT967 | Lovenox | Clexane | EMT-966 | EMT 966 | EMT966 |
|
Chemical Information |
Molecular Formula |
C26H42N2O37S5 |
CAS Registry Number |
9005-49-6 |
SMILES |
CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(
C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O |
Chemical Structure |
|
|
ADR Related Proteins Induced by Drug |
ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
Not Available | Not Available | Not Available | Not Available | Not Available |
|
ADRs Induced by Drug |
ADR Term |
ADReCS ID |
ADR Frequency (FAERS)
|
ADR Severity Grade (FAERS)
|
ADR Severity Grade (CTCAE)
|
Anti factor X activity increased | 13.01.02.044 | 0.001049% | | Not Available |
|
|
|